Cover Image

Cutaneous Side Effects of Single Versus Combined BRAF Inhibitors: A Comment to Erfan et al.

Saved in:

Bibliographic Details
Main Authors:	Rachel Anforth (Author), Pablo Fernandez-Penas (Author)
Format:	Book
Published:	Medical Journals Sweden, 2017-09-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature
by: Bilgen Gençler, et al.
Published: (2016)

Clinico-economic analysis of PD-1 inhibitors and combinations of BRAF and MEK inhibitors for the treatment of metastatic melanoma with a BRAF V600 gene mutation
by: D. Yu. Belousov, et al.
Published: (2018)

Cutaneous sarcoidosis due to immune‐checkpoint inhibition and exacerbated by a novel BRAF dimerization inhibitor
by: J. P. Pham, et al.
Published: (2021)

BRAF/MEK inhibitor-induced remission of primary cutaneous myoepithelial carcinoma after local recurrence
by: Jacqueline Guidry, MD, et al.
Published: (2020)

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing
by: Gulietta M. Pupo, et al.
Published: (2017)

Clinical and economic analysis of treatment sequences with prolgolimab and BRAF/MEK inhibitors in adult patients with metastatic or unresectable cutaneous melanoma
by: S. K. Zyryanov, et al.
Published: (2024)

Correlation of histopathological patterns in cutaneous melanoma with BRAF mutations Correlação de padrões histopatológicos de melanomas cutâneos com mutações BRAF
by: Juliana Elizabeth Jung, et al.
Published: (2010)

Granulomatous Reactions from Tattoos Following BRAF Inhibitor Therapy
by: Gabrielle Giet, et al.
Published: (2019)

High BRAF V600 Mutation Level Associated with Worse Outcome in Metastatic Melanoma Patients Receiving BRAF and MEK Inhibitors
by: Ariane Fizazi, et al.
Published: (2024)

Impact of posaconazole and diltiazem on pharmacokinetics of encorafenib, a BRAF V600 kinase inhibitor for melanoma and colorectal cancer with BRAF mutations
by: Erik Hahn, et al.
Published: (2023)

A case of malignant transformation of a serous borderline ovarian tumor effectively treated with BRAF/MEK inhibitor combination
by: Manrose Singh, et al.
Published: (2024)

Economic evaluation of adverse events of dabrafenib plus trametinib versus nivolumab in patients with advanced BRAF-mutant cutaneous melanoma for adjuvant therapy in Germany
by: S Wahler, et al.
Published: (2021)

Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy
by: Raphael Reinhard, MD, et al.
Published: (2018)

Use of BRAF inhibitor (Vemurafenib) in a child with Refractory Langerhans cell histiocytosis
by: Anil Sharma, et al.
Published: (2017)

Erdheim-Chester disease BRAF (-) Diagnosis through cutaneous manifestations and good response with anakinra treatment
by: Juan-Manuel, et al.
Published: (2024)

BRAF, KIT, NRAS, GNAQ and GNA11 mutation analysis in cutaneous melanomas in Turkish population
by: Ismail Yilmaz, et al.
Published: (2015)

Banded versus Single-sided bonded space maintainers: A Comparative Study
by: Sudhir Mittal, et al.
Published: (2018)

Combinatorial Therapies to Overcome BRAF/MEK Inhibitors Resistance in Melanoma Cells: An in vitro Study
by: Pópulo H, et al.
Published: (2021)

Immune check point inhibitors in BRAF mutated metastatic colorectal cancer: A review
by: Alfredo Colombo, et al.
Published: (2024)

BRAF mutations in cutaneous melanoma: no correlation with histological prognostic factors or overall survival Mutações BRAF em melanomas cutâneos: nenhuma correlação com fatores prognósticos e sobrevida global
by: Juliana Elizabeth Jung, et al.
Published: (2010)

Dermoscopic Features as Predictors of BRAF Mutational Status and Sentinel Lymph Node Positivity in Primary Cutaneous Melanoma
by: Nika Filipović, et al.
Published: (2021)

Impressive clinical response following combined BRAF and MEK inhibition in a low-grade serous ovarian carcinoma patient with a BRAF V600E mutation
by: Anna Rodzajewska, et al.
Published: (2023)

Durable response to BRAF inhibitor monotherapy in recurrent metastatic low grade serous ovarian cancer
by: Shashank Sama, et al.
Published: (2024)

A diagnostic dilemma: Atypical melanocytic lesions arising in the setting of treatment with the BRAF inhibitor, vemurafenib
by: Mary Clark, MD, et al.
Published: (2022)

Cutaneous Side Effects Of D-Penicillamine
by: Faghini G, et al.
Published: (2003)

Cutaneous side effects of sports supplements
by: Sujata M Ambalal, et al.
Published: (2024)

Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase
by: Valerie Glutsch, et al.
Published: (2020)

Treatment of metastatic malignant melanoma during pregnancy with a BRAF kinase inhibitor: A case report
by: Megan Pagan, et al.
Published: (2019)

Therapeutic Effectiveness of Immunoradiotherapy on Brain-metastatic BRAF/MEK Inhibitor-resistant Melanoma with Balloon Cell Change
by: Haruka Goto, et al.
Published: (2019)

Targeting Non-V600 Mutations in BRAF: A Single Institution Retrospective Analysis and Review of the Literature
by: Hirra A. Chaudhary, et al.
Published: (2024)

BRAF Mutations and Resistance of Non-Small Cell Lung Cancer to BRAF-Targeted Therapies Using Liquid Biopsy
by: Ming Li, et al.
Published: (2021)

BRAF Mutation Heterogeneity in Melanoma Lesions
by: Kaori Sakaizawa, et al.
Published: (2020)

Dabrafenib for treatment of BRAF-mutant melanoma
by: Kainthla R, et al.
Published: (2013)

BRAF mutation in hairy cell leukemia
by: Ahmad Ahmadzadeh, et al.
Published: (2014)

A topical BRAF inhibitor (LUT-014) for treatment of radiodermatitis among women with breast cancerCapsule Summary
by: Sanford Katz, MD, et al.
Published: (2024)

Agents to treat BRAF-mutant lung cancer
by: Jean G Bustamante Alvarez, et al.
Published: (2019)

Side Effects Comparison of Coronavirus Vaccines Among Healthcare Workers: Comment
by: Amnuay Kleebayoon, et al.
Published: (2023)

SOX4 Mediates BRAF Inhibitor Resistance in Melanoma through Regulation of IGF-1R Signaling: In Vitro Study
by: Xiao Liu, et al.
Published: (2020)

Localized Epidermal Cysts as a Radiation Recall Phenomenon in a Melanoma Patient Treated with Radiotherapy and the BRAF Inhibitor Vemurafenib
by: Carine Houriet, et al.
Published: (2014)

Differential Effects of the Oncogenic BRAF Inhibitor PLX4032 (Vemurafenib) and its Progenitor PLX4720 on ABCB1 Function
by: Martin Michaelis, et al.
Published: (2014)